Saturday , October 21 2017
Home / Resources / Articles / FDA Approves OptiClik(TM), New Insulin Pen System from Aventis

FDA Approves OptiClik(TM), New Insulin Pen System from Aventis

Precision delivery device offers an additional tool to help people with diabetes achieve their treatment targets with once-daily LANTUS®

“The OptiClik(TM) pen will provide people with diabetes with a new and easy-to-use delivery option, one that will complement Lantus(R), the first and only 24-hour basal insulin analog,” said Kim Carroll, Vice President, Diabetes at Aventis.

"With the approval of OptiClik(TM), Aventis furthers its goal of offering people with diabetes an integrated system of insulin products and choice of delivery devices to achieve precision dosing and meet their needs for blood glucose control," adds John Harrington, Vice President Metabolism Business Unit at Aventis. Insiders report that Aventis will be offering their new fast acting Insulin, Apidra, in the same pen.